Global economic overview and outlook:
The global healthcare and medical device industry continues to remain an important and rapidly evolving sector, supported by increasing healthcare expenditure, technological advancements, ageing populations, rising incidence of chronic diseases and growing demand for accessible and affordable healthcare solutions. The medical device industry is characterised by continuous innovation, stringent quality and regulatory requirements and increasing adoption of advanced technologies.
The global medical device industry continues to witness structural growth, driven by increasing demand for diagnostic, monitoring, therapeutic and surgical devices. Technological developments such as digital healthcare, connected medical devices, artificial intelligence, remote monitoring, wearable technologies and advanced diagnostics are creating new opportunities for manufacturers and healthcare product companies.
The industry is also witnessing a gradual shift towards localisation of manufacturing and diversification of global supply chains. Healthcare systems across various countries are seeking reliable suppliers and cost-effective solutions, thereby creating opportunities for manufacturers from emerging markets. Increasing emphasis on quality, regulatory compliance and supply-chain resilience is expected to remain a key factor influencing the industry.
Medical device companies are often operating in clusters due to the requirement for cross-functional support, specialised manpower, research and development facilities, hospitals and healthcare institutions for product development and testing, and availability of quality raw materials. Such clusters are present across major global markets including the United States, Europe, Japan, China, South Korea, Brazil and Australia.
Going forward, the global medical devices sector is expected to remain on a growth trajectory. Companies having diversified product portfolios, strong customer relationships, quality manufacturing capabilities, regulatory expertise and the ability
to respond quickly to changing healthcare requirements are expected to be better positioned to benefit from the long-term growth of the industry.
Indian Economy Overview and Outlook:
India continues to emerge as one of the important markets for medical devices globally. The Indian medical devices industry is supported by increasing healthcare expenditure, expansion of healthcare infrastructure, increasing penetration of health insurance, rising awareness regarding preventive healthcare and growing demand for quality healthcare products.
The Indian medical devices market is projected to grow substantially over the coming years. Current industry estimates indicate that the market could increase from approximately US$15.2 billion in 2025 to around US$50.1 billion by 2030. The growth is expected to be supported by rising healthcare demand, expanding infrastructure, increasing investments and greater adoption of medical technology.
The Government of India continues to provide policy support to strengthen domestic manufacturing capabilities and reduce dependence on imports. Initiatives such as the Production Linked Incentive (PLI) Scheme for medical devices, the National Medical Devices Policy, medical device parks and schemes supporting research, innovation and capacity building are contributing to the development of the domestic medical technology ecosystem.
The medical devices sector is also witnessing increasing investments in manufacturing and technology. The Government has stated that the PLI Scheme has resulted in the commencement of manufacturing of several high-end medical devices in India, while investments in medical-device infrastructure and testing facilities are continuing to increase.
Indias export potential in medical devices is also expanding. Medical device exports increased significantly in recent years, reflecting Indias growing capabilities in manufacturing affordable and quality healthcare products. The industry has opportunities to further expand its global footprint by leveraging Indias cost competitiveness, skilled manpower and expanding manufacturing ecosystem. Industry estimates indicate that Indian medical device exports could grow substantially by 2030.
The overall outlook for the Indian medical devices sectors therefore remains positive. Increasing healthcare requirements, government support, technological development, export opportunities and localisation of manufacturing are expected to create sustainable growth opportunities for companies operating in the sector.
Financial and Operational Performance:
During FY 2025-26, the Company continued to maintain its focus on its core business of manufacturing and trading of medical devices, disposables and other healthcare products.
Revenue from operations during FY 2025-26 stood at approximately Rs.4,202.70 lakh, as compared to Rs.3,839.01 lakh during FY 2024-25, representing an increase of approximately 9.47%.
Total revenue during the year stood at approximately Rs.4,269.64 lakh, compared with Rs.3,970.84 lakh in the previous financial year, representing a growth of approximately 7.52%.
The Companys profit before tax stood at approximately Rs.320.45 lakh, compared with Rs.429.77 lakh in FY 2024-25. Profit after tax stood at approximately Rs.231.10 lakh, compared with Rs.333.85 lakh in the previous year.
The reduction in profitability, despite growth in revenue, was primarily attributable to the change in the product and business mix, increase in certain operating expenses and the overall cost structure during the year. Other income also decreased from approximately Rs.131.83 lakh in FY 2024-25 to Rs.66.94 lakh in FY 2025-26.
The Companys earnings per share on a basic basis stood at approximately Rs.2.67 per share during FY 2025-26 as compared to Rs.3.96 per share in FY 2024-25.
During the year, the Company also witnessed a change in the composition of its sales. Manufactured product sales were approximately Rs.2,452.66 lakh, while trading sales were approximately Rs.1,750.03 lakh. The increased contribution from trading activities reflects the Companys continued efforts to expand its product portfolio and respond to market demand.
The Companys management remains focused on improving operational efficiency, strengthening its product portfolio, maintaining quality standards, expanding customer relationships and improving profitability through better cost management and appropriate product and business mix.
STRENGTH
• We offer a diversified range of medical devices, disposables and healthcare products.
• Existing well-established reputation and customer relationships.
• Focus on quality assurance and compliance with applicable regulatory requirements.
• Established presence in the healthcare products segment.
• Experienced management team with industry expertise and a successful track record.
• Ability to operate through a combination of manufacturing and trading activities, providing flexibility in responding to market requirements.
• Focus on customer satisfaction, product availability and timely delivery.
• Established relationships with customers and business partners in domestic as well as international markets.
COMPETITION:
We face competition from organised as well as unorganised players in the healthcare and medical devices industry having presence across various regions in India and international markets. Various companies offer products and services that are similar or complementary to those offered by the Company.
We believe that the principal elements of competition in our industry include price, product quality, durability, regulatory compliance, product availability, timely delivery, customer service, reliability and, importantly, the ability to keep pace with technological and healthcare developments.
The medical devices industry is also witnessing increasing competition from both domestic manufacturers and international players. The Companys ability to maintain its competitive position depends upon its product quality, pricing, customer relationships, distribution capabilities, manufacturing efficiency and ability to introduce or offer products that meet changing market requirements.
To remain competitive, the Company continues to focus on improving its manufacturing and operating capabilities, expanding its product offerings, maintaining quality standards and strengthening its customer relationships. The Company also seeks opportunities for new product registrations, marketing authorisations and expansion of its product portfolio.
Risks and Concerns:
The Companys business is exposed to various risks including changes in market demand, competition, raw material prices, foreign exchange fluctuations, regulatory requirements, technological changes, supply-chain disruptions and changes in healthcare policies.
The medical device industry is subject to stringent quality and regulatory requirements. Any change in applicable laws, regulations, standards or approval requirements may increase compliance costs or affect the Companys ability to market certain products.
The Company is also exposed to competition from domestic and international players. Competitive pricing pressure may affect margins and profitability. Changes in raw material costs and availability may also have an impact on the Companys cost structure.
Changes in the product mix may influence the Companys margins and overall profitability. During FY 2025-26, although the Company recorded growth in revenue from operations, profitability declined compared with the previous year. Management continues to monitor costs, product margins, inventory levels and business mix with a view to improving operating efficiency.
The Company seeks to mitigate these risks through diversification of its product portfolio, maintaining relationships with multiple customers and suppliers, monitoring market developments, strengthening internal controls and ensuring compliance with applicable statutory and regulatory requirements.
The Management Discussion and Analysis section primarily consists of statements that may include forward-looking predictions based on perceptions and are, as a result, subject to potential risks and uncertainties. It encompasses the collective sum of the Companys expectations, beliefs, assessments and projections. Actual results may differ materially from those expressed or implied herein. Shareholders are advised to consider these factors in conjunction with the Companys financial statements.
Internal Control Systems and their adequacy:
The Company maintains a robust system of internal financial controls to ensure that its financial statements are accurate and reliable. The internal control framework is designed to safeguard the Companys assets, optimise operational efficiency, ensure proper authorisation of transactions and support timely and accurate financial reporting.
The internal control systems are designed to ensure compliance with applicable policies, procedures, laws and regulations. The Company continuously reviews and strengthens its internal control mechanisms commensurate with the size and complexity of its operations.
During the year, the Companys internal controls were reviewed and monitored by the management and the Audit Committee. The management is committed to continuously testing and improving the effectiveness of internal control systems.
The Audit Committee plays an important role in reviewing the Companys financial reporting, internal audit observations and other matters relating to internal controls. Significant observations, wherever identified, are reviewed and appropriate corrective measures are taken.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.